Literature DB >> 16690488

Myeloblast phenotypic changes in myelodysplasia. CD34 and CD117 expression abnormalities are common.

Samuel J Pirruccello1, Ken H Young, Patricia Aoun.   

Abstract

We used a new method of data presentation and analysis, termed antigen mapping, to characterize recurring myeloblast phenotypic abnormalities in a series of 28 cases of myelodysplastic syndrome (MDS), including refractory anemia with ringed sideroblasts (RARS), refractory anemia with multilineage dysplasia (RCMLD), and refractory anemia with excess blasts (RAEB). Abnormal patterns of CD34 and CD117 expression were present in 50% of RARS, 68% of RCMLD, and 100% of RAEB cases. The presence of decreased myeloblast CD45 density, increased CD13 and CD34 density, and increased expression of CD11c and CD4(dim) were MDS grade-related. There was a direct relationship between the number of myeloblast phenotypic abnormalities (phenotypic score) and MDS grade. The myeloblast phenotypic scores also were correlated highly with International Prognostic Scoring System scores and risk categories. We found the antigen mapping technique to be an efficient data presentation and analysis method for the detection of MDS-associated abnormalities of antigen distribution and density.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16690488     DOI: 10.1309/j3et7rxd1x4bkdlf

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  4 in total

1.  Fulminant EBV-driven CD8 T-cell lymphoproliferative disorder following primary acute EBV infection: a unique spectrum of T-cell malignancy.

Authors:  Ken H Young; Dahua Zhang; Jeffery T Malik; Eliot C Williams
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

2.  Flow cytometric immunophenotyping: emerging as an important diagnostic tool in the evaluation of cytopenic patients.

Authors:  Maryalice Stetler-Stevenson
Journal:  Leuk Res       Date:  2009-03-26       Impact factor: 3.156

3.  Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study.

Authors:  Kiyoyuki Ogata; Matteo G Della Porta; Luca Malcovati; Cristina Picone; Norio Yokose; Akira Matsuda; Taishi Yamashita; Hideto Tamura; Junichi Tsukada; Kazuo Dan
Journal:  Haematologica       Date:  2009-06-22       Impact factor: 9.941

4.  Correlation Between Bone Marrow Blasts Counts With Flow Cytometry and Morphological Analysis in Myelodysplastic Syndromes.

Authors:  Min Huang; Xinya Zhao; Hongzhi Xu; Suqing Liu; Zie Wang; Xiaohui Sui; Jing Li
Journal:  Ann Lab Med       Date:  2017-09       Impact factor: 3.464

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.